Turning Insights Into Action: Linda Sullivan and Ken Getz on How Metrics and Benchmarking Provide a Path To Optimizing Clinical Trials
In this episode, Linda chats with the incomparable Ken Getz, the Deputy Director and a professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine, where he conducts research focusing on drug development management and operating strategies and tactics; protocol design practices; and global outsourcing, investigative site, and patient recruitment practices and policies. Getz describes how the Center chooses topics for study, which can emanate from passionate industry professionals or from information gleaned at conferences and then implemented through working groups. At any given time, the Center is working on 12-15 studies, including recent research on participant diversity in clinical trials and upcoming research on possible reduction in time between phases (white space) in clinical trials and patient-centered initiatives. The pandemic has acted as an accelerator in a variety of areas, including remote and virtual visits, telemedicine, and data management, which could result in increased customization and choices to support clinical trials, according to Getz. It’s an exciting time for clinical trial professionals as new technology, including AI, increasingly comes into play. And in the TRIO segment, you’ll want to hear Getz’s answers to these questions: What the biggest challenge facing the clinical trials industry? What’s the best new innovation? What‘s your top optimization takeaway?